ArticleInternational journal of molecular sciences2025
Structure-Based Engineering of a PTPsigma Ectodomain for Enhanced Solubility and Productivity.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Protein tyrosine phosphatase receptor sigma (PTPRS) regulates cellular signals involved in hematopoietic stem cell development, synaptic plasticity, and synovium differentiation. The soluble extracellular Ig-like domains of PTPRS have therapeutic potential by binding to a ligand, inhibiting the ligand-binding of endogenous PTPRS. However, the wild-type Ig-like domains have poor solubility, which limits their therapeutic use. In this study, we identified solvent-exposed hydrophobic residues on the surface of PTPRS and mutated the residues to hydrophilic residues for solubility-enhancing engineering. The mutagenesis screening increased its solubility up to five-fold. In addition, the expression yields were also increased by up to 14-fold. The biochemical and functional analysis of the engineered PTPRS showed that the mutant protein had comparable properties to the wild type. Thus, the engineered PTPRS has potential for therapeutic applications where modulation of PTPRS is critical.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.